Androisoxazole (brand names Androxan, Neo-Ponden, Neo-Pondus), also known as 17α-methyl-5α-androstano[3,2-c]isoxazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT) that is marketed in Spain and Italy. It is closely related to stanozolol, differing only in having an isoxazole instead of pyrazole ring fused to the A ring, and is also related to furazabol, prostanozol, and danazol.
|Trade names||Androxan, Neo-Ponden, Neo-Pondus|
|Drug class||Androgen; Anabolic steroid|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||329.484 g·mol−1|
|3D model (JSmol)|
- Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN 978-3-88763-075-1.
- Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 384–. ISBN 978-3-642-66353-6.
- ANTONINI FM, VERDI G (October 1961). "[Preliminary results of experience with a new anabolic steroid, "androisoxazole," in the aged.]". Minerva Medica (in Italian). 52: 3437–41. PMID 13861810.
- ARNOLD A, POTTS GO, BEYLER AL (December 1963). "Relative Oral Anabolic to Androgenic Activity Ratios of Androisoxazole, Ethylestrenol, Methylandrostenolisoxazole and Testosterone". Acta Endocrinologica. 44 (4): 490–8. doi:10.1530/acta.0.0440490. PMID 14082537.
|This article about a steroid is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|